X4 Pharmaceuticals

124 articles with X4 Pharmaceuticals

• X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and Development

  9/18/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Renato Skerlj, Ph.D., as Senior Vice President, Research and Development.

• X4 Pharmaceuticals to Attend Two Upcoming Investor Conferences - Sept. 17, 2019

  9/17/2019

  X4 Pharmaceuticals, Inc. announced that the management team is scheduled to conduct one-on-one meetings at the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies, and to present and conduct one-on-one meetings at the 2019 Cantor Global Healthcare Conference.

• X4 Pharmaceuticals to Present Phase 2a Data for Mavorixafor in Combination with Axitinib at European Society for Medical Oncology (ESMO) 2019 Congress

  9/12/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical stage biotechnology company focused on the development of novel therapeutics for the treatment of rare diseases, today announced it will present clinical data on its lead product candidate, mavorixafor (X4P-001), in combination with Inlyta® (axitinib) at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress, taking place September 27 – October 1 in Barcelona, Spain.

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug. 29, 2019

  8/29/2019

  X4 Pharmaceuticals, Inc. announced that, on August 28, 2019, the Compensation Committee of X4’s Board of Directors issued inducement awards to two new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  8/6/2019

  X4 Pharmaceuticals, Inc. announced that on August 2, 2019 the Compensation Committee of X4’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 12,000 shares of its common stock to 4 new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.

• X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome

  7/30/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the European Commission (EC), based on a favorable recommendation from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation (ODD) to mavorixafor (X4P-001) for the treatment of WHIM

• X4 Pharmaceuticals to Attend Two Upcoming Investor Conferences

  7/24/2019

  Management team is scheduled to present at the 39th Annual Canaccord Genuity Growth Conference, and to conduct one-on-one meetings at the BTIG Biotechnology Conference 2019.

• X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM Syndrome

  6/26/2019

  X4 Pharmaceuticals, Inc. (Nasdaq:XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of 4WHIM, a pivotal Phase 3 global clinical trial of mavorixafor (X4P-001) for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary immunodeficiency disease.

• X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease

  6/12/2019

  Genetic testing to enable improved patient diagnoses and provide valuable disease-specific genetic insights for X4 clinical development of novel therapies

• X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia

  5/15/2019

  Mavorixafor selected for LLS’s Therapy Acceleration Program® (TAP)

• X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer

  4/24/2019

  Dr. Kelley brings more than a decade of experience driving clinical development and global expansion of novel pharmaceutical products at both emerging and established life sciences companies.

• X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants

  4/12/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering of 5,670,000 shares of its common stock

• X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants

  4/11/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and Class A warrants to purchase its common stock. All of the securities in the offering will be sold by X4.

• X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors

  4/2/2019

  Dr. Stewart currently serves as Chief Medical Officer of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing therapies for the treatment of rare genetic disorders of obesity.

• X4 Pharmaceuticals Provides Business and Clinical Development Update

  4/1/2019

  Expects to commence the global Phase 3 pivotal trial of mavorixafor for the treatment of patients with Warts, Hypogammaglobulinemia, Infections and Myelokathexis syndrome in second quarter 2019 having finalized the protocol based on FDA guidance

• X4 Pharmaceuticals Completes Merger with Arsanis

  3/13/2019

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR, as of March 14, 2019), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the completion of its merger with Arsanis, Inc. (Nasdaq: ASNS, through March 13, 2019), effective as of March 13, 2019.

• X4 Pharmaceuticals Presents Additional Positive Phase 2 Results for X4P-001 in WHIM Syndrome, Continues on Path to Initiation of Phase 3 Trial

  12/1/2018

  X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 allosteric antagonist drugs to improve immune cell trafficking to treat rare diseases and cancer, today announced the presentation of additional Phase 2 clinical data demonstrating a positive safety profile and clinical activity of X4P-001 in patients with WHIM syndrome, a rare primary immunodeficiency disease.

• 

  In Reverse Merger with Arsanis, X4 Pharmaceuticals Will Begin to Trade on the Nasdaq

  11/27/2018

  Shares of Arsanis, Inc. stock are up more than 25 percent in premarket trading after the company announced that it will merge with privately-held X4 Pharmaceuticals, Inc. as part of a reverse merger that will provide X4 with a quick path to being traded on the Nasdaq.

• X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity through CXCR4 Antagonism

  11/6/2018

  X4 Pharmaceuticals, today highlighted data from a poster presentation of a clinical study with X4P-001-IO, an investigational CXCR4 allosteric antagonist, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, being held November 7-11, 2018, in Washington, D.C.

• X4 Pharmaceuticals Appoints Gary J. Bridger, PhD, to Board of Directors

  11/5/2018

  Leader brings expertise in financing, corporate planning and R&D strategy for biotechnology companies